Express Pharma

DECEMBER 2, 2024

By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.

Labelling 126

Labelling Diabetes Drug Development 126

Pharmaceutical Technology

JUNE 7, 2023

The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

European Pharmaceutical Review

JULY 31, 2024

billion in 2023 for its obesity and diabetes blockbuster drugs Ozempic (off-label for obesity) and Wegovy respectively, facilitated the growth. Mounjaro, Zepbound, and Ozempic are expected to surpass Merck & Co’s Keytruda in global analyst consensus sales by 2030″ This is despite an “overall 1.6 Global sales of $13.9

Diabetes 52

Diabetes Labelling 52

Quality Matters

SEPTEMBER 9, 2024

The area is populated with apps and other software designed to treat various ailments including mental health disorders, diabetes, asthma, insomnia, substance-use disorders, and beyond. billion in 2024 to over 32 billion in 2030. Patients can often use them from the comfort of their homes.

Labelling 52

Labelling Diabetes 52

PharmaShots

APRIL 3, 2023

old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The results also showed a reduction in risk of hospitalization for any cause with 14% relative risk reduction (24.8

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40